A Philadelphia-area biotech is developing therapies for neurodegenerative diseases it says have the potential to perform better than others by targeting multiple proteins involved in the brain’s breakdown.
Now the company, Berwyn, PA-based Annovis Bio, has raised $12 million in an initial public offering to advance clinical development of its lead therapy in patients with Alzheimer’s disease, Parkinson’s disease, and people with Down syndrome who have developed Alzheimer’s.
The company, which listed on the NYSE American stock exchange under the stock symbol “ANVS,” sold about 4 million shares at $6 apiece, the low end of its projected range of $6 to… Read more »
UNDERWRITERS AND PARTNERS
